Terminated trial tests First-of-its-Kind treatment for kids with rare nerve disease
NCT ID NCT06681766
Summary
This study aimed to test the safety of a new drug called nomlabofusp in children and teenagers with Friedreich's ataxia, a rare genetic disorder that damages the nervous system. The trial was small, involving about 18 participants, and was designed to see how their bodies handled the drug when given as a daily injection for one week. It was an early-stage study that has since been terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uncommon Cures
Chevy Chase, Maryland, 20815, United States
Conditions
Explore the condition pages connected to this study.